Programme
ABC6 - Final Programme
Available HERE
All pre-recorded lectures will be available on-demand starting 15 October, 09:00 CET (date and time to be confirmed)
|
Patient advocacy session: Managing your Mind: stress, anxiety, depression and resilience Chairs: Shirley A. Mertz, US and Claire Myerson UK |
|
|
How to diagnose and manage stress, anxiety and depression in ABC patients. What is resilience and how to develop it? Luzia Travado, PT |
30 min |
|
Patient Experiences Panel Panel of experts: Theresa Wiseman, UK – Shani Paluch Shimon, IL Gloria Okwu, NG – Boon Lui Sew, MY - Nelly Perez, MX |
40 min |
|
|
|
|
Patient advocacy session: Can big data and artificial intelligence help ABC patients? Chairs: Renate Haidinger, DE and Kim Sabelko, US |
|
|
Technology-based PROMs and AI-driven decision support: the example of CANKADO Timo Schinköthe, DE |
15 min |
|
Emerging Pathomics – The role of AI pathology Frédérique Penault-Llorca, FR |
15 min |
|
A new tool: BCNA Symptom tracker Kirsten Pilatti, AU |
15 min |
|
Advancing ABC management through AI/Big data Fatima Cardoso, PT |
15 min |
|
|
|
|
Patient advocacy session: Oncobrain: Not an excuse but a common reality Chairs: Ginny Mason, US and Elizabeth Bergsten-Nordstrom, SE |
|
|
What is it? How do you know you have it? Ginny Mason, US and Elizabeth Bergsten-Nordstrom, SE |
30 min |
|
How to diagnose and to manage Onco-brain? Berta Sousa, PT |
30 min |
|
|
|
|
Patient advocacy session: Global Inequalities in access to clinical trials Chairs: Eva Schumacher, DE and Runcie C.W. Chidebe, NG |
|
|
Global inequalities in access to ABC clinical trials in LMICs: Challenges and opportunities – the African perspective |
15 min |
|
Global inequalities in access to ABC clinical trials in LMICs: Challenges and opportunities – the Latin-American perspective |
15 min |
|
Patient Experiences Panel Panel of experts (TBC) : Alexandru Eniu, CH – Gertrude Nakigudde, UG Bertha Aguilar, MX – Ranjit Kaur, MY – Bishal Gyawali, CA Dany Habr, US – Carlos Barrios, BR – Funmi Olopade, US |
40 min |
|
Challenges on evaluating patients with ABC Chairs: Christoph Thomssen, DE and Frédéric E. Lecouvet, BE |
|
|
Re-defining progressive disease: oligo-progression, pseudo-progression, endocrine flare Karen Gelmon, CA |
15 min |
|
How to act in discordant biomarker results (primary vs mets vs other mets) Aleix Prat, ES |
15 min |
|
Optimal timing and interval of imaging for ABC (clinical practice & trials) George W. Sledge, US |
15 min |
|
Is it time to change the follow-up guidelines for early BC - aka - is it worthwhile to detect metastatic disease earlier? Ann H. Partridge, US |
15 min |
|
Best abstract presentations Chairs: Alberto Costa, IT/CH and Renate Haidinger, DE |
|
|
Measuring knowledge, skills and confidence in metastatic breast cancer nursing: The Cancer Nurse Self-Assessment Tool for Metastatic Breast Cancer (CaN-SAT-MBC) |
10 min |
|
From early to metastatic breast cancer: A systematic review and meta-analysis of distant recurrence rates |
10 min |
|
A national study of the experiences, information needs and attitudes to clinical research of patients living with secondary breast cancer in the UK |
10 min |
|
Emotional distress, brain functioning, social well-being and biobehavioral processes in metastatic breast cancer patients: outcomes of the DistressBrain Project |
10 min |
|
The standards in 2021 Chairs: Elzbieta Senkus, PL and Bertha Aguilar, MX |
|
|
Current standard of care for HER2+ ABC Sandra M. Swain, US |
15 min |
|
Current standard of care for Triple Negative ABC Giuseppe Curigliano, IT |
15 min |
|
Current standard of care for ER+/HER2 neg ABC Nadia Harbeck, DE |
15 min |
|
Biology Medley Chairs: William J. Gradishar, US and Sung-Bae Kim, KR |
|
|
Beyond overexpression/amplification of HER2 Giuseppe Viale, IT |
15 min |
|
Predictive biomarkers for immune-checkpoint inhibitors: lost or found? Frédérique Penault-Llorca, FR |
15 min |
|
Biomarkers of resistance/response to endocrine-based therapy. What's ready for clinical practice? Nicholas Turner, UK |
15 min |
|
Hereditary breast cancer: which markers besides gBRCA? Shani Paluch-Shimon, IL |
15 min |
|
Who's caring for the carers? Chairs: Olivia Pagani CH, Lesley Fallowfield UK and Barbara Wilson, UK |
|
|
Spouses, Children, Parents: psychological issues Luzia Travado, PT |
15 min |
|
What do carers need to care Theresa Wiseman, UK |
15 min |
|
Health Care Providers: Compassionate fatigue Michal Braun, IL |
15 min |
|
What's new in the management of inoperable inflammatory (IBC) and locally advanced breast cancer (LABC) Chairs: Ginny Mason, US and Daniel A. Vorobiof, US |
|
|
Have we improved our knowledge about biology? Sofia D. Merajver, US |
15 min |
|
Systemic management of inoperable inflammatory breast cancer: any news? Hamouda Boussen, TN |
15 min |
|
Optimal loco-regional management Maria Joao Cardoso, PT |
15 min |
|
What should be updated in the ABC guidelines for systemic therapy for inoperable LABC and IBC? Joseph Gligorov, FR |
20 min |
|
From manageable to tolerable: focus on side effects Chairs: Shinji Ohno, JP and Eva Schumacher, DE |
|
|
Pneumonitis/Interstitial Lung Disease (ILD) Hope S. Rugo, US |
15 min |
|
Immune-related toxicity Carlos H. Barrios, BR |
15 min |
|
Preventing and treating cardiotoxicity Evandro de Azambuja, BE |
15 min |
|
The role of cannabis for ABC patients Matti S. Aapro, CH |
15 min |
|
Oligometastatic disease and specific sites of metastases Chairs: Shani Paluch-Shimon, IL and Ranjit Kaur, MY |
|
|
Re-defining oligo-metastatic disease and its systemic management Prudence A. Francis, AU |
15 min |
|
SBRT and new radiotherapy techniques for metastatic disease Birgitte V. Offersen, DK |
20 min |
|
Optimal management of peritoneal carcinomatosis and ascites Nagi El Saghir, LB |
15 min |
|
Drug development for ABC Chairs: Jonas Bergh, SE and Kirsten Pilatti, AU |
|
|
Antibody-drug conjugates: delivering chemotherapy at the tumor's doorsteps Javier Cortés, ES |
15 min |
|
Newer therapeutic options for triple negative ABC Rebecca A. Dent, SG |
15 min |
|
New drug interactions and consequences Alessandra Gennari, IT |
15 min |
|
Is the maximum tolerated dose (MDT) still the optimal goal for cancer drugs? Larry Norton, US |
15 min |
|
Managing ABC during a pandemic Chairs: Elizabeth Bergsten-Nordström, SE and Binghe Xu, CN |
|
|
Lessons learned from COVID-19 Laura Biganzoli, IT |
15 min |
|
The ABC of vaccination for advanced breast cancer patients Alexandru Eniu, CH |
15 min |
|
Strengths and limitations of tele-medicine for ABC patients Fran Boyle, AU |
15 min |
SPONSORED SATELLITE SYMPOSIA (on-demand)
|
Daiichi Sankyo/AstraZeneca sponsored satellite symposium: A team approach to the treatment of patients with HER2-postive metastatic breast cancer |
|
|
Lilly sponsored satellite symposium: Beyond the doors of MDT meeting: impact on HR+HER2- breast cancer patients. |
|
|
Novartis sponsored satellite symposium: What matters to patients with HR+ HER2– ABC: Expanding options for living better for longer |
|
|
Pfizer sponsored satellite symposium: Raising awareness of underserved patient populations: Solutions from the real world |
|
|
Seagen sponsored satellite symposium: Multidisciplinary team perspectives on the evolving treatment landscape in HER2+ MBC |
|
Sponsored satellite symposia programmes available here.
During the live discussion sessions, all speakers from the respective on-demand session will be present live to further discuss their lectures.
Discussions will be facilitated by distinguished chairs and co-chairs.
|
4 NOVEMBER 2021 |
||
|
Starting Time: 14:00 CET (San Francisco 6:00, New York 9:00, Lisbon 13:00, Kuala Lumpur 21:00, Melbourne/Sydney 00:00) |
||
|
14:00 |
Opening session |
|
|
14:05 |
Opening and welcome to a new era of ABC |
15 min |
|
14:20 |
Opening Lecture: Europe’s Beating Cancer Plan and advanced cancer patients Stella Kyriakides, European Commissioner for Health and Food Safety, BE |
20 min |
|
14:40 |
Keynote lecture: The fight against mBC – is this a battle I can win?” Eva Schumacher, DE |
25 min |
|
15:05 |
ABC Award and Lecture |
20 min |
|
15:25-15:30 |
Technical break |
5 min |
|
15:30 |
Live Q&A: Biology Medley Chairs: William J. Gradishar, US and Sung-Bae Kim, KR Speakers: Shani Paluch-Shimon, IL - Frédérique Penault-Llorca, FR Nicholas Turner, UK - Giuseppe Viale, IT |
20 min |
|
15:50-15:55 |
Technical break |
5 min |
|
15:55 |
Live Q&A: Challenges on evaluating patients with ABC Chairs: Christoph Thomssen, DE and Frédéric E. Lecouvet, BE Speakers: Karen Gelmon, CA - Aleix Prat, ES George W. Sledge, US - Ann H. Partridge, US |
20 min |
|
16:15-16:20 |
Technical break |
5 min |
|
16:20 |
Live Q&A: The standards in 2021 Chairs: Elzbieta Senkus, PL and Bertha Aguilar, MX Speakers: Giuseppe Curigliano, IT - Nadia Harbeck, DE Sandra M. Swain, US |
20 min |
|
16:40-16:45 |
Technical break |
5 min |
|
16:45 |
Q&A – Best Abstracts Chairs: Fatima Cardoso, PT - Alberto Costa, IT/CH - Renate Haidinger, DE |
15 min |
|
17:00 |
End of live sessions day 1 |
|
During the live discussion sessions, all speakers from the respective on-demand session will be present live to further discuss their lectures.
Discussions will be facilitated by distinguished chairs and co-chairs.
|
5 NOVEMBER 2021 |
||
|
Starting Time: 14:00 CET (San Francisco 6:00, New York 9:00, Lisbon 13:00, Kuala Lumpur 21:00, Melbourne/Sydney 00:00) |
||
|
13:30-13:45 |
Live Q&A: Seagen sponsored satellite symposium |
15 min |
|
13:45-14:00 |
Technical break |
15 min |
|
14:00 |
Live Q&A: Patient advocacy session Can big data and artificial intelligence help ABC patients? Chairs: Renate Haidinger, DE and Kim Sabelko, US Speakers: Fatima Cardoso, PT - Kirsten Pilatti, AU - Timo Schinköthe, DE - Frédérique Penault Llorca, FR |
20 min |
|
14:20-14:25 |
Technical break |
5 min |
|
14:25 |
Live Q&A: Drug development for ABC |
20 min |
|
14:45-14:50 |
Technical break |
5 min |
|
14:50 |
Live Q&A: Oligometastatic disease and specific sites of metástases Chairs: Shani Paluch-Shimon, IL and Ranjit Kaur, MY Speakers: Nagi El Saghir, LB - Prudence A. Francis, AU Birgitte V. Offersen, DK |
15 min |
|
15:05-15:10 |
Technical break |
5 min |
|
15:10 |
Live Q&A: Patient advocacy session: Global Inequalities in access to clinical trials Chairs: Eva Schumacher, DE and Runcie C.W. Chidebe, NG Speakers: Dany Habr, US – Alexandru Eniu, CH Gertrude Nakigudde, UG – Bertha Aguilar, MX – Ranjit Kaur MY – Bishal Gyawali, CA – Carlos Barrios, BR – Funmi Olopade, US |
15 min |
|
15:25-15:30 |
Technical break |
5 min |
|
15:30 |
Live Q&A: From manageable to tolerable: focus on side effects Chairs: Shinji Ohno, JP and Eva Schumacher, DE Speakers: Matti S. Aapro, CH - Carlos H. Barrios, BR Evandro de Azambuja, BE - Hope S. Rugo, US |
20 min |
|
15:50-15:55 |
Technical break |
5 min |
|
15:55 |
Live Q&A: Managing ABC during a pandemic Chairs: Elizabeth Bergsten-Nordström, SE and Binghe Xu, CN Speakers: Laura Biganzoli, IT – Fran Boyle, AU, Alexandru Eniu, CH |
20 min |
|
16:15-16:20 |
Technical break |
5 min |
|
16:20 |
Live Q&A: Patient advocacy session: Oncobrain: Not an excuse but a common reality Chairs: Elizabeth Bergsten-Nordstrom, SE – Karen Gelmon, CA Ginny Mason, US Speaker: Berta Sousa, PT |
15 min |
|
16:35-16:40 |
Technical break |
5 min |
|
16:40 |
Live Q&A: What's new in the management of inoperable inflammatory (IBC) and locally advanced breast cancer (LABC) Chairs: Ginny Mason, US and Daniel A. Vorobiof, US Speakers: Hamouda Boussen, TN - Maria Joao Cardoso, PT Joseph Gligorov, FR - Sofia D. Merajver, US |
20 min |
|
17:00-17:05 |
Technical break |
5 min |
|
17:05 |
Live Q&A: Who's caring for the carers? Chairs: Olivia Pagani CH, Lesley Fallowfield UK and Barbara Wilson, UK Speakers: Luzia Travado, PT - Theresa Wiseman, UK |
20 min |
|
17:25 |
End of live sessions day 2 |
|
|
17:25-17:30 |
Technical break |
5 min |
|
17:30-17:45 |
Live Q&A: Daiichi Sankyo/AstraZeneca sponsored satellite symposium |
15 min |
The Advanced Breast Cancer International Consensus Conference will close as usual with an update of the Consensus session where discussion will focus on updating the ABC guidelines.
The Consensus will take place on Saturday afternoon, 6th November.
The consensus session will not be recorded and will only be available live.
|
6 NOVEMBER 2021 |
||
|
Starting Time: 14:00 CET (San Francisco 6:00, New York 9:00, Lisbon 13:00, Kuala Lumpur 21:00, Melbourne/Sydney 00:00) |
||
| 13:30-13:45 | Live Q&A: Pfizer sponsored satellite symposium | 15 min |
|
13:45-14:00 |
Break |
15 min |
|
14:00 |
Consensus session Part I ABC6 Chairs, Scientific Committee Members and Panellists |
|
|
16:00 |
Break |
15 min |
|
16:15 |
Consensus session Part II ABC6 Chairs, Scientific Committee Members and Panellists |
|
|
17:45 |
Closing remarks Fatima Cardoso, PT |
5 min |
|
17:50 |
End of live sessions day 3 |
|
Representatives of breast cancer patient advocacy groups are warmly invited to participate in ABC6 and actively contribute to the scientific programme and consensus session.
Furthermore, in collaboration with several leading breast cancer patient advocacy groups worldwide, specific additional patient advocacy sessions will be scheduled.
Breast Cancer Patient Advocacy Committee
Coordinator
Fatima Cardoso, ABC Global Alliance, Lisbon, PT
Bertha Aguilar Lopez, MILC Foundation, Mexico City, MX
Elizabeth Bergsten-Nordstrom, Europa Donna - The European Breast Cancer Coalition, SE
Maria João Cardoso, MamaHelp Association, Lisbon, PT
Runcie C.W. Chidebe, Project PINKBLUE, Abuja, NG
Renate Haidinger, Brustkrebs Deutschland e.V., Munich, DE
Ranjit Kaur, Breast Cancer Welfare Association, Pataling Jaya, MY
Ginny Mason, Inflammatory Breast Cancer Research Foundation, West Lafayette, US
Shirley A. Mertz, MBC US Alliance and Metastatic Breast Cancer Network US, Inverness, US
Claire Myerson, Breast Cancer Now, London, UK
Gertrude Nakigudde, Uganda Women's Cancer Support Organisation, Kampala, UG
Kirsten Pilatti, Breast Cancer Network Australia, Camberwell, AU
Kim Sabelko, Susan G. Komen, Washington, US
Eva Schumacher-Wulf, Mamma Mia, Kronberg, DE
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |